GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Net Current Asset Value

Abbisko Cayman (HKSE:02256) Net Current Asset Value : HK$3.22 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Abbisko Cayman's net current asset value per share for the quarter that ended in Dec. 2023 was HK$3.22.

The historical rank and industry rank for Abbisko Cayman's Net Current Asset Value or its related term are showing as below:

HKSE:02256' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.82   Med: 1.13   Max: 1.9
Current: 0.94

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Abbisko Cayman was 1.90. The lowest was 0.82. And the median was 1.13.

HKSE:02256's Price-to-Net-Current-Asset-Value is ranked better than
88.34% of 1029 companies
in the Biotechnology industry
Industry Median: 3.96 vs HKSE:02256: 0.94

Abbisko Cayman Net Current Asset Value Historical Data

The historical data trend for Abbisko Cayman's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Net Current Asset Value Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-0.76 -1.89 4.80 3.91 3.22

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial 4.80 4.50 3.91 3.63 3.22

Competitive Comparison of Abbisko Cayman's Net Current Asset Value

For the Biotechnology subindustry, Abbisko Cayman's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbisko Cayman's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Price-to-Net-Current-Asset-Value falls into.



Abbisko Cayman Net Current Asset Value Calculation

Abbisko Cayman's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2232.842-146.873-0-0)/647.858
=3.22

Abbisko Cayman's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2232.842-146.873-0-0)/647.858
=3.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman  (HKSE:02256) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Abbisko Cayman Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman (HKSE:02256) Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Xu Yao-chang 2101 Beneficial owner
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited 2301 Trustee
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you

Abbisko Cayman (HKSE:02256) Headlines

No Headlines